



July 25, 2017, PD Dr. med. Günter Schneider

“Concepts to target pancreatic cancer”

In summary the research interest of PD Dr. Schneider’s includes disturbed cell cycle regulation, mechanisms of therapeutic resistance, epigenetic changes, altered signaling and metastasis in pancreatic ductal adenocarcinoma (PDAC) and other GI-cancers in vitro and in vivo. Several substantial experiments were carried out in a panel of human cell lines such as breast and colon cancer cells and primary chronic lymphatic leukemia cells as well as human and murine pancreatic cancer cells. Especially, one of his ongoing research focuses is to establish novel concepts to target the relevant drivers of PDAC. Additionally, his research group pays closer attention on the role of oncogenic KRAS and the oncogenic transcription factor MYC and their interaction with epidermal growth factor receptor signalling. Consistent with this, his research team further elucidates the downstream targets of this signalling network. Research activities include the usage of a novel model system utilizing murine primary pancreatic ductal epithelial cells (PDECs), genetically engineered to allow time-specific expression of oncogenic KRAS from the endogenous promoter.

Yasin Bahadir Erol and Benedikt Niedermaier